Curated News
By: NewsRamp Editorial Staff
August 07, 2026
Quantum BioPharma's Dual Strategy Targets MS and Alcohol Misuse
TLDR
- Quantum BioPharma advances Lucid-MS and unbuzzd, targeting FDA Phase 2 trial and commercial sales, potentially boosting investor returns.
- Quantum BioPharma's Lucid-MS targets PAD2 enzyme to protect myelin, with IND filed for Phase 2 and imaging collaboration with Mass General.
- Quantum BioPharma's therapies aim to restore myelin in MS and reduce alcohol harm, improving quality of life for patients.
- Quantum BioPharma's unbuzzd supplement claims to reduce hangover effects, backed by a randomized placebo-controlled trial.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough in multiple sclerosis treatment that could shift the paradigm from immune modulation to direct myelin repair, offering hope for millions affected by this debilitating disease. Additionally, the development of unbuzzd addresses alcohol misuse, a significant public health issue, with a novel approach to mitigating acute intoxication and hangover symptoms. For investors, Quantum BioPharma's progress in clinical trials and strategic partnerships signals potential growth in the biotech sector, making it a stock to watch.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a dual-pronged strategy to address neurological health, focusing on multiple sclerosis (MS) and alcohol misuse. The company's investigational therapy, Lucid-MS, targets PAD2, an enzyme linked to myelin degradation, with the goal of protecting and potentially restoring the myelin sheath, unlike conventional treatments that primarily modulate the immune system. Quantum BioPharma has submitted an Investigational New Drug (IND) application to the FDA for a Phase 2 trial and is collaborating with Massachusetts General Hospital on imaging to support development. In parallel, the company offers unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover effects, citing results from a randomized, placebo-controlled clinical trial.
The company's pipeline reflects a commitment to innovative treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse. Lucid-MS, developed through its wholly-owned subsidiary Lucid Psycheceuticals Inc., is a patented new chemical entity that has shown promise in preclinical models to prevent and reverse myelin degradation. Quantum BioPharma also spun out the over-the-counter version of unbuzzd to Unbuzzd Wellness Inc. (UWI), retaining a 19.84% ownership stake as of March 31, 2026, and entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop pharmaceutical formulations of unbuzzd.
To read the full article, visit https://ibn.fm/Rl89U. For the latest news on QNTM, see the company's newsroom at https://ibn.fm/QNTM. This content is disseminated on behalf of Quantum BioPharma and may include paid advertising.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Dual Strategy Targets MS and Alcohol Misuse
